Skip to main content
PMC home page
Gut logoLink to Gut
. 1996 Mar;38(3):447–453. doi: 10.1136/gut.38.3.447

Increased concentrations of tumour necrosis factor (TNF) and soluble TNF receptors in biliary obstruction in mice; soluble TNF receptors as prognostic factors for mortality.

M H Bemelmans 1, J W Greve 1, D J Gouma 1, W A Buurman 1
PMCID: PMC1383077  PMID: 8675101

Abstract

Systemic tumour necrosis factor (TNF) is present in jaundiced mice. Two soluble TNF receptors, sTNFr-P55 and sTNFr-P75 are reported to play a part in the natural defence against TNF. This study investigated the properties of circulating TNF and sTNFr in jaundiced mice. The data show that TNF in these mice is biologically inactive and that an increase of both sTNFr is seen (p < 0.001). Surgical trauma in jaundiced mice is known to be accompanied by a high mortality (36%) and increased TNF concentrations. This study shows that both systemic TNF and sTNFr concentrations are increased after surgical trauma in jaundiced mice and that sTNFr concentrations rather than TNF concentrations were found to be correlated with mortality. In line with this finding this study showed that lactulose pretreatment before a surgical trauma in these mice significantly reduces postoperative concentrations of sTNFr-P75 (p < 0.005) and mortality (0%; p < 0.05) without reducing TNF concentrations, while anti-TNF antibodies were ineffective. In conclusion, these data suggest that TNF in biliary obstruction is rapidly inactivated by increased concentrations of sTNFr. Furthermore, sTNFr concentrations rather than TNF concentrations show a good correlation with mortality after surgery in obstructive jaundice. The positive effect of lactulose on mortality could be caused by a decreased inflammatory status.

Full text

PDF
447

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992 Feb 1;175(2):323–329. doi: 10.1084/jem.175.2.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bemelmans M. H., Gouma D. J., Buurman W. A. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol. 1993 Mar 1;150(5):2007–2017. [PubMed] [Google Scholar]
  3. Bemelmans M. H., Gouma D. J., Buurman W. A. LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma. J Immunol. 1993 Nov 15;151(10):5554–5562. [PubMed] [Google Scholar]
  4. Bemelmans M. H., Gouma D. J., Greve J. W., Buurman W. A. Cytokines tumor necrosis factor and interleukin-6 in experimental biliary obstruction in mice. Hepatology. 1992 Jun;15(6):1132–1136. doi: 10.1002/hep.1840150626. [DOI] [PubMed] [Google Scholar]
  5. Bemelmans M. H., Gouma D. J., Greve J. W., Buurman W. A. Effect of antitumour necrosis factor treatment on circulating tumour necrosis factor levels and mortality after surgery in jaundiced mice. Br J Surg. 1993 Aug;80(8):1055–1058. doi: 10.1002/bjs.1800800845. [DOI] [PubMed] [Google Scholar]
  6. Better O. S., Massry S. G. Effect of chronic bile duct obstruction on renal handling of salt and water. J Clin Invest. 1972 Feb;51(2):402–411. doi: 10.1172/JCI106826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Beutler B., Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987 Feb 12;316(7):379–385. doi: 10.1056/NEJM198702123160705. [DOI] [PubMed] [Google Scholar]
  8. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  9. Brockhaus M., Bar-Khayim Y., Gurwicz S., Frensdorff A., Haran N. Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int. 1992 Sep;42(3):663–667. doi: 10.1038/ki.1992.332. [DOI] [PubMed] [Google Scholar]
  10. Brockhaus M., Schoenfeld H. J., Schlaeger E. J., Hunziker W., Lesslauer W., Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A. 1990 Apr;87(8):3127–3131. doi: 10.1073/pnas.87.8.3127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Clements W. D., Halliday M. I., McCaigue M. D., Barclay R. G., Rowlands B. J. Effects of extrahepatic obstructive jaundice on Kupffer cell clearance capacity. Arch Surg. 1993 Feb;128(2):200–205. doi: 10.1001/archsurg.1993.01420140077012. [DOI] [PubMed] [Google Scholar]
  12. Cope A. P., Aderka D., Doherty M., Engelmann H., Gibbons D., Jones A. C., Brennan F. M., Maini R. N., Wallach D., Feldmann M. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 1992 Oct;35(10):1160–1169. doi: 10.1002/art.1780351008. [DOI] [PubMed] [Google Scholar]
  13. Dejong C. H., Kampman M. T., Deutz N. E., Soeters P. B. Altered glutamine metabolism in rat portal drained viscera and hindquarter during hyperammonemia. Gastroenterology. 1992 Mar;102(3):936–948. doi: 10.1016/0016-5085(92)90180-7. [DOI] [PubMed] [Google Scholar]
  14. Dentener M. A., Greve J. W., Maessen J. G., Buurman W. A. Role of tumour necrosis factor in the enhanced sensitivity of mice to endotoxin after exposure to lead. Immunopharmacol Immunotoxicol. 1989;11(2-3):321–334. doi: 10.3109/08923978909005373. [DOI] [PubMed] [Google Scholar]
  15. Dixon J. M., Armstrong C. P., Duffy S. W., Davies G. C. Factors affecting morbidity and mortality after surgery for obstructive jaundice: a review of 373 patients. Gut. 1983 Sep;24(9):845–852. doi: 10.1136/gut.24.9.845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Engelmann H., Holtmann H., Brakebusch C., Avni Y. S., Sarov I., Nophar Y., Hadas E., Leitner O., Wallach D. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem. 1990 Aug 25;265(24):14497–14504. [PubMed] [Google Scholar]
  17. Engelmann H., Novick D., Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990 Jan 25;265(3):1531–1536. [PubMed] [Google Scholar]
  18. Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods. 1986 Dec 4;95(1):99–105. doi: 10.1016/0022-1759(86)90322-4. [DOI] [PubMed] [Google Scholar]
  19. Froon A. H., Bemelmans M. H., Greve J. W., van der Linden C. J., Buurman W. A. Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. Crit Care Med. 1994 May;22(5):803–809. doi: 10.1097/00003246-199405000-00015. [DOI] [PubMed] [Google Scholar]
  20. Greve J. W., Gouma D. J., von Leeuwen P. A., Buurman W. A. Lactulose inhibits endotoxin induced tumour necrosis factor production by monocytes. An in vitro study. Gut. 1990 Feb;31(2):198–203. doi: 10.1136/gut.31.2.198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Greve J. W., Maessen J. G., Tiebosch T., Buurman W. A., Gouma D. J. Prevention of postoperative complications in jaundiced rats. Internal biliary drainage versus oral lactulose. Ann Surg. 1990 Aug;212(2):221–227. doi: 10.1097/00000658-199008000-00018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hamilton G., Hofbauer S., Hamilton B. Endotoxin, TNF-alpha, interleukin-6 and parameters of the cellular immune system in patients with intraabdominal sepsis. Scand J Infect Dis. 1992;24(3):361–368. doi: 10.3109/00365549209061344. [DOI] [PubMed] [Google Scholar]
  23. Hansen M. B., Nielsen S. E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods. 1989 May 12;119(2):203–210. doi: 10.1016/0022-1759(89)90397-9. [DOI] [PubMed] [Google Scholar]
  24. Hishida A., Honda N., Sudo M., Nagase M. Mechanisms of altered renal perfusion in the early stage of obstructive jaundice. Kidney Int. 1980 Feb;17(2):223–230. doi: 10.1038/ki.1980.25. [DOI] [PubMed] [Google Scholar]
  25. Holman J. M., Jr, Rikkers L. F. Biliary obstruction and host defense failure. J Surg Res. 1982 Mar;32(3):208–213. doi: 10.1016/0022-4804(82)90092-0. [DOI] [PubMed] [Google Scholar]
  26. Maessen J. G., Greve J. W., Buurman W. A. Increased sensitivity to endotoxemia by tissue necrosis. Surgery. 1991 Feb;109(2):154–159. [PubMed] [Google Scholar]
  27. Millar A. B., Foley N. M., Singer M., Johnson N. M., Meager A., Rook G. A. Tumour necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome. Lancet. 1989 Sep 23;2(8665):712–714. doi: 10.1016/s0140-6736(89)90772-1. [DOI] [PubMed] [Google Scholar]
  28. Pain J. A., Bailey M. E. Experimental and clinical study of lactulose in obstructive jaundice. Br J Surg. 1986 Oct;73(10):775–778. doi: 10.1002/bjs.1800731003. [DOI] [PubMed] [Google Scholar]
  29. Peetre C., Thysell H., Grubb A., Olsson I. A tumor necrosis factor binding protein is present in human biological fluids. Eur J Haematol. 1988 Nov;41(5):414–419. doi: 10.1111/j.1600-0609.1988.tb00220.x. [DOI] [PubMed] [Google Scholar]
  30. Petersen C. M., Møller B. K. Immunological reactivity and bioactivity of tumour necrosis factor. Lancet. 1988 Apr 23;1(8591):934–935. doi: 10.1016/s0140-6736(88)91735-7. [DOI] [PubMed] [Google Scholar]
  31. Pinto M., Kaplun A. Immune status in mice with experimental biliary obstruction. Clin Immunol Immunopathol. 1980 Aug;16(4):396–405. doi: 10.1016/0090-1229(80)90181-6. [DOI] [PubMed] [Google Scholar]
  32. Pitt H. A., Cameron J. L., Postier R. G., Gadacz T. R. Factors affecting mortality in biliary tract surgery. Am J Surg. 1981 Jan;141(1):66–72. doi: 10.1016/0002-9610(81)90014-3. [DOI] [PubMed] [Google Scholar]
  33. Röllinghoff M., Warner N. L. Specificity of in vivo tumor rejection assessed by mixing immune spleen cells with target and unrelated tumor cells. Proc Soc Exp Biol Med. 1973 Dec;144(3):813–818. doi: 10.3181/00379727-144-37688. [DOI] [PubMed] [Google Scholar]
  34. Sheehan K. C., Ruddle N. H., Schreiber R. D. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol. 1989 Jun 1;142(11):3884–3893. [PubMed] [Google Scholar]
  35. Spinas G. A., Keller U., Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest. 1992 Aug;90(2):533–536. doi: 10.1172/JCI115891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Tanaka N., Ryden S., Bergqvist L., Christensen P., Bengmark S. Reticulo-endothelial function in rats with obstructive jaundice. Br J Surg. 1985 Dec;72(12):946–949. doi: 10.1002/bjs.1800721204. [DOI] [PubMed] [Google Scholar]
  37. Van Bossuyt H., Desmaretz C., Gaeta G. B., Wisse E. The role of bile acids in the development of endotoxemia during obstructive jaundice in the rat. J Hepatol. 1990 May;10(3):274–279. doi: 10.1016/0168-8278(90)90132-b. [DOI] [PubMed] [Google Scholar]
  38. Van Zee K. J., Kohno T., Fischer E., Rock C. S., Moldawer L. L., Lowry S. F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4845–4849. doi: 10.1073/pnas.89.11.4845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Waage A., Halstensen A., Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987 Feb 14;1(8529):355–357. doi: 10.1016/s0140-6736(87)91728-4. [DOI] [PubMed] [Google Scholar]
  40. Wait R. B., Kahng K. U. Renal failure complicating obstructive jaundice. Am J Surg. 1989 Feb;157(2):256–263. doi: 10.1016/0002-9610(89)90540-0. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES